Outcomes of Chemotherapies and HER2 Directed Therapies in Advanced HER2-mutant Lung Cancers

Lung Cancer - Netherlands
doi 10.1016/j.lungcan.2016.05.030
Full Text
Abstract

Available in full text

Date
Authors
Publisher

Elsevier BV

Related search

Author Correction: HER Kinase Inhibition in Patients With HER2- And HER3-mutant Cancers

Nature
Multidisciplinary
2019English

P088 Distribution of Different HER2 Mutations and Their Impact on Clinical Responses to Afatinib in HER2-Mutant Lung Cancer

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

ZW25 Active in HER2-positive Cancers

Cancer Discovery
Oncology
2018English

Update on HER2-directed Therapy

Breast Cancer Research
Cancer ResearchOncology
2005English

Use of Novel Combination Therapies in the Treatment of Advanced HR+/HER2− Breast Cancer

Journal of the National Comprehensive Cancer Network : JNCCN
MedicineOncology
2018English

P1.01-110 Three Specific HER2 Mutations Predict Favorable Outcomes in Advanced Lung Cancer Patients Treated With Afatinib

Journal of Thoracic Oncology
MedicineOncologyRespiratory MedicinePulmonary
2018English

The Role of HER2 in Early Breast Cancer Metastasis and the Origins of Resistance to HER2-targeted Therapies

Experimental and Molecular Pathology
Forensic MedicinePathologyClinical BiochemistryMolecular Biology
2009English

Assessment of ERBB2/HER2 Status in HER2-Equivocal Breast Cancers by FISH and 2013/2014 ASCO-CAP Guidelines

JAMA Oncology
Cancer ResearchOncology
2019English

Dual Characteristics of Novel HER2 Kinase Domain Mutations in Response to HER2-Targeted Therapies in Human Breast Cancer

Clinical Cancer Research
Cancer ResearchOncology
2016English

Amanote Research

Note-taking for researchers

Follow Amanote

© 2024 Amaplex Software S.P.R.L. All rights reserved.

Privacy PolicyRefund Policy